Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection

BACKGROUND Cushing's disease is a rare endocrine disorder caused by the overproduction of adrenocorticotropic hormone (ACTH) from a corticotroph pituitary adenoma. It accounts for approximately 15% of all pituitary adenomas and has a female predominance (4:1). Cushing's disease is associated with increased mortality, substantial morbidity, and a notable impact on health-related quality of life. Diagnosis involves a variety of assessments, including demonstration of autonomous ACTH-driven hypercortisolaemia, inferior petrosal sinus sampling to exclude an ectopic source of ACTH production and MRI of the pituitary gland to identify a pathological pituitary adenoma.

Trans-sphenoidal surgical (TSS) resection of a pituitary adenoma remains the primary treatment. However, the surgical cure rate only ranges between 60% and 80% and therefore, repeated pituitary surgery, pituitary radiotherapy, or bilateral adrenalectomy are often required to achieve cure. Pre-operative medical (cortisol-lowering) therapy reduces both morbidity and perioperative complications. Both ketoconazole and metyrapone have been used as cortisol-lowering treatments, but effectiveness can be variable and adverse side effects are often significant necessitating dose reduction.

Osilodrostat, a potent inhibitor of the enzyme 11-beta-hydroxylase has been shown to be highly effective in normalising urinary free cortisol levels and achieving clinical remission in patients with Cushing's disease. The Phase III LINC-3 study investigated the efficacy and safety of osilodrostat in patients with Cushing's disease who were ineligible for pituitary surgery or had previously undergone unsuccessful pituitary surgery. The trial revealed that osilodrostat successfully normalised urinary free cortisol levels in a significant proportion of patients leading to improvements in clinical signs and symptoms of Cushing's disease. Importantly, the study reported a very favourable side effect and safety profile for Osilodrostat.

In Cushing's disease, dedicated pituitary MRI only identifies a suitable surgical target in 60% of cases. Recently, 11C-methionine PET/CT has emerged as a valuable additional tool for the localisation of pituitary lesions not clearly identified with conventional MRI. 11C-methionine is taken up by peptide-secreting cells via the L-type amino acid transporter 1 (LAT1), which is expressed in pituitary tissue, including pituitary adenomas. Functioning pituitary adenomas such as somatotroph adenomas, prolactinomas and, to a lesser extent, corticotroph adenomas, show increased uptake of 11C-methionine compared to normal pituitary tissue, and this can allow accurate localisation of small tumours that are not clearly visualised on anatomical imaging, as well as discriminate between post-surgical tissue re-modelling and residual tumour in patients who have undergone previous unsuccessful surgery.

Treatment with osilodrostat is associated with an increase in circulating ACTH levels, reflecting reduction in adrenal glucocorticoid biosynthesis by osilodrostat with consequent attenuation of negative feedback by cortisol at the level of the hypothalamus and pituitary, but also corticotroph pituitary adenomas, as corticotroph adenomas, albeit autonomously ACTH-producing, appear to retain a degree of feedback regulation. The investigators predict that the lack of negative feedback may lead to an increase in corticotroph tumour activity, thereby improving radiological detection of corticotroph tumours not seen on imaging prior to osilodrostat treatment.

The investigators therefore hypothesise that a period of medical treatment with osilodrostat may enhance the detection and localisation of corticotroph adenomas by using 11C-methionine PET.

RATIONALE FOR CURRENT STUDY Even with the adoption of modern and innovative MR sequences, an important subgroup of corticotroph tumours cannot be readily localised. Whilst the introduction of molecular imaging with 11C-methionine PET/CT can aid detection of a proportion of such occult tumours, we believe that detection could be further enhanced by repeating 11C-methionine PET/CT following a period of medical treatment. The possible increase in tumoral activity during the period of medical treatment would be anticipated to correlate with increased 11C-methionine uptake. A period of treatment with osilodrostat (the most effective cortisol-lowering medical treatment available) prior to surgery and resulting reduced negative feedback due to reduction of excess cortisol levels, might in turn enhance the clarity of both conventional and functional imaging and might aid the identification of previously occult adenomas.

STUDY OBJECTIVES This observational study is to investigate whether the combination of treatment with osilodrostat and 11C-methionine PET/CT may help to identify occult/ equivocal pituitary corticotroph adenomas in patients with Cushing's disease.

• Change in 11C-methionine SUVmax in a presumed corticotroph adenoma through comparison of pre- and post-osilodrostat 11C-methionine PET/CT.

STUDY DESIGN OPTIMAL is a single-arm observational study. The inclusion and exclusion criteria are listed in Section 4, but in brief, the study population will consist of adult patients diagnosed with Cushing's disease according to Endocrine Society Guidelines with no/ an equivocal surgical target on MRI pituitary.

The visit schedule and data collection are detailed in appendix.

STUDY OUTCOME MEASURES Primary outcome • Tumour activity on functional imaging Change in 11C-methionine SUVmax in a corticotroph adenoma through comparison of pre- and post-osilodrostat 11C-methionine PET/CT.

Secondary outcomes

• Radiological tumour appearance Change in MRI appearance of a presumed corticotroph adenoma pre- and post-osilodrostat treatment.

INCLUSION CRTERIA

All participants must meet all of the following inclusion criteria:

• age 18 years and older newly diagnosed with Cushing's disease and no/ an equivocal surgical target on MRI pituitary or
• age 18 years and older and previously undergone pituitary surgery for Cushing's disease and clinical and biochemical evidence of persistent/ recurrent hypercortisolaemia and no/ an equivocal surgical target on MRI pituitary.

EXCLUSION CRITERIA

Potential participants will be ineligible to enter the study if they meet any of the following exclusion criteria:

• Absolute contraindication to osilodrostat therapy and/or 11C methionine PET.
• Pregnancy or unwillingness to use secure contraception for the study duration (female participants only).
• Unable to comply with study visit schedule.

STUDY PROCEDURE A total of 15 patients with confirmed Cushing's disease will be enrolled and undergo baseline assessments including MRI of the pituitary gland and 11C-methionine PET/CT. Patients will start medical therapy with osilodrostat as per our local standard practice and will follow a titration regimen as described in the Phase III LINC-3 study, with the aim to normalise UFC levels for a period of at least 3 months.

Preferably, an osilodrostat titration-based approach will be used and a block-and-replace regimen will be reserved for patients in whom normalisation of cortisol levels cannot safely be achieved with titration of osilodrostat alone. After a 3-month period of eucortisolaemia, patients will undergo a second MRI of the pituitary gland and 11C-methionine PET/CT scan with SUVmax ratio analysis of the presumed corticotroph pituitary adenoma.

Comparison between the first and second 11C-methionine PET/CT will be carried out and a change of >20% in SUVmax constitutes a positive result.

Additionally, this observational study will collect data on biochemical markers of bone health, cardiovascular health, hypercoagulopathy, and quality of life. However, it is important to note that such data are for descriptive purposes only and are being collected as they may be useful as groundwork for a potential larger prospective study in the future.